86 related articles for article (PubMed ID: 6542371)
21. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma.
McKenna DB; Marioni JC; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Sep; 151(3):636-44. PubMed ID: 15377351
[TBL] [Abstract][Full Text] [Related]
22. [Phase III study of bestatin in patients with malignant skin tumors. (1) Malignant melanoma].
Ikeda S; Ishihara K; Taguchi G
Gan To Kagaku Ryoho; 1985 Jan; 12(1):77-85. PubMed ID: 3881086
[TBL] [Abstract][Full Text] [Related]
23. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
Sánchez-Ortiz R; Huang SF; Tamboli P; Prieto VG; Hester G; Pettaway CA
J Urol; 2005 Jun; 173(6):1958-65. PubMed ID: 15879790
[TBL] [Abstract][Full Text] [Related]
24. [Surgical management of orbital malignant melanoma: our experience and a report of three cases].
Poli T; Mora P; Reichegger V; Ricci R; Corradi D; Gandolfi SA; Sesenna E
Klin Monbl Augenheilkd; 2007 Oct; 224(10):794-8. PubMed ID: 17952825
[TBL] [Abstract][Full Text] [Related]
25. [The present status of the multidisciplinary treatment of malignant melanoma].
Ishihara K; Hayasaka K; Ikegawa S; Kageshita T
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1073-8. PubMed ID: 4057571
[TBL] [Abstract][Full Text] [Related]
26. Prognostic variables for patients with stage III malignant melanoma.
Messaris GE; Konstadoulakis MM; Ricaniadis N; Leandros E; Androulakis G; Karakousis PC
Eur J Surg; 2000 Mar; 166(3):233-9. PubMed ID: 10755339
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
Mordoh J; Kairiyama C; Bover L; Solarolo E
Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
[TBL] [Abstract][Full Text] [Related]
28. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
29. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
30. [Malignant melanoma in German-speaking countries in the 80's. Initial results of the central registry for malignant melanoma of the Germany Society of Dermatology in cooperation with the federal health office].
Garbe C; Bertz J; Orfanos CE
Hautarzt; 1987 Nov; 38(11):639-44. PubMed ID: 3501419
[TBL] [Abstract][Full Text] [Related]
31. Melanoma in children and the use of sentinel lymph node biopsy.
Bütter A; Hui T; Chapdelaine J; Beaunoyer M; Flageole H; Bouchard S
J Pediatr Surg; 2005 May; 40(5):797-800. PubMed ID: 15937817
[TBL] [Abstract][Full Text] [Related]
32. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial.
Romeo F; Arcoria D; Palmisano L; Polosa P
Arzneimittelforschung; 1985; 35(8):1317-22. PubMed ID: 3907642
[TBL] [Abstract][Full Text] [Related]
35. [Improved immunocompetence in two children with chronic Epstein-Barr virus infection under treatment with a standardized thymus hormone preparation (thymostimulin)].
Pernice W; Schneider H; Wais U; Stier R; Forster J
Arzneimittelforschung; 1985; 35(5):869-70. PubMed ID: 2992532
[TBL] [Abstract][Full Text] [Related]
36. [Nitrosomethylurea in the treatment of patients with disseminated cutaneous melanoma].
Dement'eva NP; Koroleva LA
Vopr Onkol; 1984; 30(7):51-4. PubMed ID: 6464402
[TBL] [Abstract][Full Text] [Related]
37. [Adjuvant DNCB immunotherapy in malignant melanoma].
Weidner F; Djawari D
Z Hautkr; 1979 May; 54(10):436-43. PubMed ID: 473840
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient hosts.
Aiuti F; Sirianni MC; Paganelli R; Stella A; Turbessi G; Fiorilli M
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):81-6. PubMed ID: 6341261
[TBL] [Abstract][Full Text] [Related]
39. Thymostimulin in malignant pleural effusions.
Rimoldi R; Brunetta F; Fioretti M; Bandera M; Ghione M
Int J Tissue React; 1984; 6(1):53-5. PubMed ID: 6201454
[TBL] [Abstract][Full Text] [Related]
40. Thymic factor therapy for herpetic keratitis.
Pivetti-Pezzi P; De Liso P; Tamburi S; Luzi G; Sirianni MC; Palmisano L; Aiuti F
Ann Ophthalmol; 1985 Jun; 17(6):327-31. PubMed ID: 3893286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
